RxDoctor Payments Data

Miladys Delgado, NP

Nurse Practitioner · Mullica Hill, NJNPI 1194863159

Payments from drug & device makers

$5,088in general payments, 2019–2025

Across 237 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$723
  • Boehringer Ingelheim$702
  • Novo Nordisk$548
  • Amgen$503
  • Novartis$480
  • E.r. Squibb & Sons, L.L.C.$340
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$5,088100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,088 in reported general payments places this provider in the 95th percentile of 2,138 nurse practitioner providers in New Jersey.

See all nurse practitioner providers in New Jersey

Medicare billing

Part B allowed, 2024
$17,326
Medicare patients
133
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban558$698,503
XareltoRivaroxaban264$322,946
EntrestoSacubitril/Valsartan130$159,703
Repatha SureclickEvolocumab118$155,415
JardianceEmpagliflozin36$47,003
FarxigaDapagliflozin Propanediol41$45,740
Metoprolol Succinate1,224$22,593
BrilintaTicagrelor33$22,174
Repatha SyringeEvolocumab14$21,999
Dofetilide68$17,467
Praluent PenAlirocumab14$16,813
Atorvastatin Calcium816$10,947
Valsartan178$7,285
Midodrine Hcl35$6,838
Rosuvastatin Calcium326$6,382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$161$698,503558 claims
Johnson & JohnsonXarelto$165$322,946264 claims
NovartisEntresto$480$159,703130 claims
AstraZenecaFarxiga, Brilinta$723$67,91474 claims
Boehringer IngelheimJardiance$702$47,00336 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,138 nurse practitioner providers in New Jersey.

Other nurse practitioner in Mullica Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →